Lichter S, Palenicek J, Yamaguchi E, Barbacci M, Chaisson RE; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 218 (abstract no. Th.B.385).
The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
OBJECTIVE: Study the efficacy, safety and tolerance of fluconazole or clotrimazole troches in the treatment of HIV-1 positive patients with oropharyngeal candidiasis. METHODS: Patients with symptomatic, culture-proven oral candidiasis were randomized to fluconazole daily capsule (100 mg) or clotrimazole troche five times daily for 14 days. Follow-up was done on days 28 and 42. RESULTS: 24 participants have been enrolled thus far. TABULAR DATA, SEE ABSTRACT VOLUME. DISCUSSION: The use of fluconazole is related to a faster clinical response and a decreased relapse rate post-treatment. The increased percentage of culture-positive, candida in the fluconazole group may not be predictive of disease recurrence. Ongoing enrollment is necessary for further analysis.
Publication Types:
Keywords:
- Candida
- Candidiasis
- Candidiasis, Oral
- Clotrimazole
- Fluconazole
- Gastrointestinal Diseases
- HIV-1
- Humans
- Respiratory Tract Infections
Other ID:
UI: 102181951
From Meeting Abstracts